Stock VINC VINCERX PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Vincerx Pharma, Inc.

Equities

VINC

US92731L1061

Market Closed - Nasdaq
Other stock markets
 21:00:00 16/05/2024 BST 		5-day change 1st Jan Change
0.72 USD -3.73% Intraday chart for Vincerx Pharma, Inc. -13.25% -38.98%
04-26 Tech Rally Boosts Exchange-Traded Funds, Equity Futures Pre-Bell Friday MT
04-26 Vincerx Pharma Prices Public Offering of Shares, Warrants MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Tech Rally Boosts Exchange-Traded Funds, Equity Futures Pre-Bell Friday
MT
Vincerx Pharma Prices Public Offering of Shares, Warrants
MT
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data
MT
Top Premarket Decliners
MT
Vincerx Pharma, Inc. Presents Positive Preliminary Phase 1 Data for Vip236 and Updates on Pipeline Progress At the American Association for Cancer Research Annual Meeting 2024
CI
Vincerx Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Tech in Focus on -2-
DJ
Vincerx Pharma, Inc. Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
CI
Vincerx Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Vincerx Pharma Says US FDA Approved Phase 1 Trial for Potential Acute Myeloid Leukemia Treatment
MT
Vincerx Pharma, Inc. Announces FDA Clearance of IND for VIP943
CI
Vincerx Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Vincerx Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Vincerx Pharma, Inc. Presents Preclinical Data of Vip236 Monotherapy Treatment in Pdx and Metastatic Pdx Mouse Models Across Several Tumor Types
CI
Vincerx Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
CI
Vincerx Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Vincerx Pharma Announces Fda Safe to Proceed Letter for Investigational New Drug Application for Its V3 Small Molecule-Drug Conjugate Vip236
CI
Vincerx Pharma, Inc. Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022
CI
Vincerx Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Earnings Flash (VINC) VINCERX PHARMA Reports Q3 Loss $-0.80
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VINC Stock
  4. News Vincerx Pharma, Inc.
  5. Highlights